CoChat

Clinical activity of abiraterone acetate in patients with metastatic castration-resistant prostate cancer progressing after enzalutamide

Open access

The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.

Abstract

Background Abiraterone acetate and enzalutamide both improve outcomes in patients with metastatic castration-resistant prostate cancer (mCRPC). Optimal sequencing for these agents and whether cross-resistance occurs is unknown. Methods Multicentre review of patients with mCRPC treated with abiraterone acetate and prednisone after progressing on enzalutamide. Primary objective was to determine abiraterone acetate response. Results Thirty patients identified from four North American centres. At abiraterone initiation, median age was 70 years (56-84 years); 70% had ECOG performance status of 0-1; all had prior docetaxel. Median prior enzalutamide treatment duration was 41 weeks (6-95 weeks), with 70% (21 of 30) having a ≥30% prostate-specific antigen (PSA) decline. Median abiraterone acetate treatment duration was 13 weeks (1-52). No objective radiographic responses were observed. Median abiraterone time to progression (PSA, objective or symptomatic) was 15.4 weeks [95% confidence interval (CI) 10.7-20.2]. Median overall survival was 50.1 weeks (95% CI 28.3-72.0). Three patients had a ≥30% PSA decline with abiraterone. Two of these patients had PSA progression as best response with prior enzalutamide. Conclusions In this study of patients progressing after enzalutamide, treatment with abiraterone was associated with a modest response rate and brief duration of effect. Primary progression on enzalutamide may not preclude a response to abiraterone.

Overview

Integrity signals

Registry

Crossref · 10.1093/annonc/mdt138

Cites

16 of 16 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 16 references

Cited by

See all 343

Metadata

Authors
Noonan, K. L., North, S., Bitting, R. L., Armstrong, A. J., Ellard, S. L., & Chi, K. N.
Affiliations
  • BC Cancer Agency (CA)
  • Cross Cancer Institute (CA)
  • Duke University (US)
Corresponding author
Chi, K.N.
Venue
Annals of Oncology
Publisher
Elsevier BV
Published
2013-07
Volume
24
Issue
7
Pages
1802-1807
ISSN
0923-7534 (ISSN-L)
OpenAlex
W2118564089
Cited by
343
References
16
Citations by year
2026: 6 · 2025: 7 · 2024: 9 · 2023: 4 · 2022: 14 · 2021: 18 · 2020: 11 · 2019: 18 · 2018: 30 · 2017: 34 · 2016: 45 · 2015: 61 · 2014: 62 · 2013: 24
FWCI
52.00
Type
journal article
Language
en
Open access
Licence
Locations
  • Annals of Oncology (publishedVersion)
  • PubMed (publishedVersion)
  • HighWire Press Open Archive (submittedVersion)
Funders
  • Janssen, Medivation, Sanofi aventis, Dendreon, Active Biotech/Ipsen, Imclone/Ely Lilly, BMS.
  • Chi: Honoraria from Janssen and Astellas; research funding from Janssen
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
  • Health Sciences › Medicine › Oncology › Bone health and treatments
  • Health Sciences › Medicine › Urology › Prostate Cancer Diagnosis and Treatment
Keywords
abiraterone, enzalutamide, metastatic castration-resistant prostate cancer, treatment sequencing, cross-resistance, PSA response, time to progression, overall survival, androgen deprivation therapy
MeSH terms
Aged, Aged, 80 and over, Androstenes, Androstenols, Antineoplastic Agents, Benzamides, Bone Neoplasms, Humans, Kallikreins, Male, Middle Aged, Nitriles, Phenylthiohydantoin, Prostatic Neoplasms, Retrospective Studies, Randomized Controlled Trials as Topic, Treatment Outcome, Prostate-Specific Antigen, Disease-Free Survival, Drug Resistance, Neoplasm, Kaplan-Meier Estimate

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Clinical activity of abiraterone acetate in patients with metastatic castration-resistant prostate cancer progressing after enzalutamide. https://app.cochat.ai/papers/10.1093/annonc/mdt138
The paper
Noonan, K. L., North, S., Bitting, R. L., Armstrong, A. J., Ellard, S. L., & Chi, K. N. (2013). Clinical activity of abiraterone acetate in patients with metastatic castration-resistant prostate cancer progressing after enzalutamide. Annals of Oncology. https://doi.org/10.1093/annonc/mdt138

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.